
Opinion|Videos|April 25, 2024
Emerging AR Targeting Agents and CDK4/6 Inhibitors in Metastatic Prostate Cancer and Potential Impact on the Treatment Landscape
Drs. McKay and Shore discuss novel agents under investigation and their potential to target androgen receptor signaling and slow metastasis in patients with metastatic and castration-resistance prostate cancer.
Advertisement
Episodes in this series

Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
AI-generated profiles impersonate female urologists to market ED products online
2
John Sfakianos, MD, discusses evolving management of recurrent LG-IR-NMIBC
3
Doublet or triplet? Urologists weighs in on mCSPC options
4
Interpreting real-world evidence in ARPI treatment decisions, with Martin Schoen, MD, PhD
5








